SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement

Apostolova, Ivayla; Riethdorf, S; Buchert, Ralph; Derlin, Thorsten; Brenner, Winfried; Mester, János; Klutmann, Susanne

doi:10.1007/s12149-010-0383-9

Cited by 19 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPECT/CT somatostatin receptor scintigraphy increases interobserver agreement as reported in two studies: SPECT/CT kappa (k) was reported as 0.86 in both, compared to planar imaging k of 0.56 and 0.59, respectively (148,155). Furthermore, SPECT/CT allows imaging to be compressed into a single time-point at 24 hours improving the efficiency of scheduling (155).…”

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 66%

“…111 In-DTPA-octreotide imaging of neuroendocrine tumors SPECT/CT for neuroendocrine imaging was first evaluated in mixed patient groups undergoing 123 I-MIBG, 111 In-DTPA-octreotide and 123/131 I-iodine scintigraphy (20,21,145,146). Improved diagnostic accuracy of SPECT/CT over planar and SPECT imaging has been consistently reported for SRS, frequently resulting in changes to management plans (147)(148)(149)(150)(151)(152)(153)(154)(155)(156)(157). Figure 4.…”

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

“…Table 4. The precise anatomic localization of radioactivity using SPECT/CT provides insight into the etiology of uptake as benign or malignant, reducing the number of equivocal findings encountered on planar imaging (148,156,157). Furthermore, the CT component of SPECT/CT can provide valuable additional anatomic information that aids in image interpretation.…”

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

See 2 more Smart Citations

Endocrine Scintigraphy with Hybrid SPECT/CT

et al. 2014

View full text Add to dashboard Cite

Nuclear medicine imaging of endocrine disorders takes advantage of unique cellular properties of endocrine organs and tissues that can be depicted by targeted radiopharmaceuticals. Detailed functional maps of biodistributions of radiopharmaceutical uptake can be displayed in three-dimensional tomographic formats, using single photon emission computed tomography (CT) that can now be directly combined with simultaneously acquired cross-sectional anatomic maps derived from CT. The integration of function depicted by scintigraphy and anatomy with CT has synergistically improved the efficacy of nuclear medicine imaging across a broad spectrum of clinical applications, which include some of the oldest imaging studies of endocrine dysfunction.

show abstract

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 66%

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

See 1 more Smart Citation

Endocrine Scintigraphy with Hybrid SPECT/CT

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The impact of SPECT/CT on inter-rater agreement in the interpretation of SRS findings has been retrospectively studied in a series of 25 unselected patients with suspected or histologically proven NETs [38]. SRS was independently interpreted by two nuclear medicine physicians: an experienced one and an inexperienced one.…”

Section: In-111 Pentetreotide Spect/ctmentioning

confidence: 99%

SPECT/CT in neuroendocrine tumours

Schillaci

Spanu

Palumbo

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms with very varying clinical expressions. Nuclear medicine plays an important role in the imaging and treatment of these tumours. Despite the advent of several PET radiopharmaceuticals, SPECT imaging with the labelled somatostatin receptor analogue In-111 pentetreotide or with radioiodinated MIBG is still a very useful technique for evaluating patients with NETs. The aim of this review is to summarise the applications, in the study of NETs, of hybrid SPECT/CT imaging performed using these gamma-emitting radiopharmaceuticals. The combined use of SPECT and CT in hybrid devices is of value when applied to scintigraphic procedures in NETs: the addition of anatomical maps provides a precise localisation of SPECT findings and allows the exclusion of disease in sites of physiological tracer uptake. These advantages translate into better sensitivity and specificity, both of which are essential for the diagnosis and accurate staging of NETs. SPECT/CT hybrid images are able to provide additional information that improves the diagnostic accuracy and confidence of SPECT interpretation and leads to changes in therapeutic options in about 25 % of patients. Therefore, SPECT/CT should be routinely performed and considered standard practice in the diagnostic work-up and treatment planning of patients with NETs submitted to In-111 pentetreotide or radioiodinated MIBG imaging. This approach can still be used as an alternative to PET/CT options when the latter are not available.

show abstract

“…Somatostatin receptor scintigraphy is considered to be useful for several clinical indications: the localization of primary tumor, the evaluation of disease extension (staging) and the qualification for peptide receptor radionuclide therapy (PRRT). Because receptor expression on the surface of lesion cellular membranes can be Original directly correlated with the intensity of the radiopharmaceutical uptake [1] this uptake in lesions is a significant indicator in therapy stratification with the use of somatostatin analogs labeled with 90 Y or/and 177 Lu [2][3][4][5][6][7][8]. An optimized method of single photon emission computed tomography (SPECT) image reconstruction is crucial to the interpretation of SRS images of NETs.…”

Section: Introductionmentioning

confidence: 99%